Canadian Cancer Trials Group ASCO 2009 Highlights
|The Canadian Cancer Trials Group is presenting results from several trials at the American Society of Clinical Oncology Annual Meeting in Orlando, Florida, May 29-June 2, 2009.
For a complete listing follow this link ... http://www.ctg.queensu.ca/public/publications/ASCO-2009MAY18.pdf
Additionally, two Canadian Cancer Trials Group investigators will be receiving awards related to their work with the Canadian Cancer Trials Group.
Dr. Penny Bradbury has been awarded the Novartis Oncology Young Canadian Investigator Award (NOYCIA) Award for her work on the impact of brain metastases on overall survival (OS) and progression free survival (PFS) in Canadian Cancer Trials Group advanced non-small cell lung cancer (NSCLC) systemic therapy clinical trials.
NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. The program is dedicated to advancing the field of oncology through the promotion of research. This year 31 abstracts were eligible, submitted and considered by the scientific panel. Following extensive and objective deliberation, ten winners from across Canada were selected.
Dr. Rachel Goodwin has been awarded the ASCO Cancer Foundation Merit Award for her work on hypertension (HTN) in the Canadian Cancer Trials Group BR.24 trial.
A select number of ASCO Cancer Foundation Merit Awards are given annually to recognize outstanding abstracts submitted for consideration for presentation at an ASCO scientific meeting. The awards are given to oncology fellows who are first authors on selected abstracts. They are designed to promote clinical research by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings.